Fundraising Fox

Philip D. Greenberg

Investor

Venture Partner at Catalio Capital Management, LP

United States

Writes $100K – $5M checks Β· typically $1.5M

About

Philip D. Greenberg is a Professor of Oncology and Immunology at the University of Washington and an Investigator at the Parker Institute for Cancer Immunotherapy at Fred Hutchinson Cancer Research Center. His work spans immunology, immuno-oncology, cancer biology, genetic engineering, and cell therapy. He earned a BA from Washington University in St. Louis and an MD from the State University of New York, and completed his residency and postdoctoral fellowship at the University of California, San Diego.

Invests in

BiotechHealthtech

Investments

Investor

Affini-T TherapeuticsJuno TherapeuticsTargeted Genetics

Per the firm's website.

Colleagues at Catalio Capital Management, LP

Frequently asked questions

Who is Philip D. Greenberg?
Philip D. Greenberg is a Professor of Oncology and Immunology at the University of Washington and an Investigator at the Parker Institute for Cancer Immunotherapy at Fred Hutchinson Cancer Research Center. His work spans immunology, immuno-oncology, cancer biology, genetic engineering, and cell therapy. He earned a BA from Washington University in St. Louis and an MD from the State University of New York, and completed his residency and postdoctoral fellowship at the University of California, San Diego.
Where does Philip D. Greenberg work?
Philip D. Greenberg is Venture Partner at Catalio Capital Management, LP.
What does Philip D. Greenberg invest in?
Philip D. Greenberg invests in Biotech, Healthtech.
What check size does Philip D. Greenberg write?
Philip D. Greenberg typically writes checks of $100K – $5M.
What companies has Philip D. Greenberg invested in?
Investments tracked here include Affini-T Therapeutics, Juno Therapeutics, Targeted Genetics.